<DOC>
	<DOCNO>NCT02172300</DOCNO>
	<brief_summary>Study investigate whether tiotropium therapy increase duration steady-state exercise decrease dynamic static lung hyperinflation COPD patient .</brief_summary>
	<brief_title>Effect Tiotropium Exercise Tolerance Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>All patient diagnosis COPD . Patients meet follow spirometric static lung volume criterion : Patients relatively stable , mild ( stage I accord criterion American Thoracic Society ( ATS ) ; original trial protocol : moderate ) severe airway obstruction FEV1 le equal 65 % predicted value . All patient presence lung hyperinflation demonstrate thoracic gas volume ( TGV ) / functional residual capacity ( FRC ) great equal 120 % predict value determine body plethysmography Visit 1 ( day 15 ) . Male female patient ≥ 40 ≤ 70 year old . Patients cigarette smoke history 10 packyears . A packyear defined equivalent smoke one pack cigarettes per day year . Patients able perform specify procedure maintain record study period require protocol . Patients able inhale medication HandiHaler® . All patient sign Informed Consent Form accordance Good Clinical Practice ( GCP ) local legislative requirement prior participation trial . i.e. , prior prestudy washout usual pulmonary medication . Patients significant disease COPD exclude . A significant disease define either disease , opinion investigator might put patient risk participation study disease , might influence result study patient 's ability participate study . Patients clinically significant abnormal baseline hematology , blood chemistry urinalysis . If abnormality define disease list exclusion criterion , patient exclude . All patient serum glutamic oxaloacetic transaminase ( SGOT AST ) ≥ 1.5 upper limit normal range ( x ULN ) , serum glutamic pyruvic transaminase ( SGPT ALT ) ≥ 1.5 x ULN , bilirubin ≥ 1.5 x ULN , creatinine ≥ 1.5 x ULN exclude regardless clinical condition . Repeat laboratory evaluation conduct subject . Patients recent history ( i.e. , 1 year less ) myocardial infarction . Patients recent history ( i.e. , 3 year less ) heart failure , pulmonary edema , patient cardiac arrhythmia ( without symptom ) contraindication exercise indicate Protocol Appendix four ( see Section 9.5.1 Appendices 16.1.1.1 16.1.1.2 ) . Patients regular use daytime oxygen therapy . ( In center significantly decrease barometric pressure , exercise test do inhaled oxygen ) . Patients know active tuberculosis . Patients history cancer within last 5 year . Patients treat basal cell carcinoma allow . Patients history lifethreatening pulmonary obstruction history cystic fibrosis bronchiectasis . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 . Patients upper respiratory tract infection past 6 week prior Screening visit ( Visit 1 , day 15 ) runin period . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . Patients know narrowangle glaucoma . Patients history asthma , allergic rhinitis atopy total blood eosinophil count ≥ 600/mm3 . A repeat eosinophil count conduct patient . Patients treat cromolyn sodium nedocromil sodium stop medication 1 month Visit 1 ( day 15 ) . Patients treated antihistamine ( H1 receptor antagonist ) antileukotrienes stop medication 1 month Visit 1 ( day 15 ) . Patients use oral corticosteroid medication unstable dos ( i.e. , less 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e. , oral contraceptive , intrauterine device , diaphragm Norplant® ) . Patients history active alcohol drug abuse . Patients take investigational drug within 1 month 10 half life ( whichever great ) prior Screening visit ( Visit 1 , day 15 ) . Limitation exercise performance result factor fatigue exertional dyspnea arthritis leg , angina claudication . Patients participated rehabilitation program COPD within 6 week prior Visit 1 ( day 15 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>